Cardiovascular Disease among Breast Cancer Survivors

Steven S. Coughlin¹,²,*, Deepak Ayyala¹, Ban Majeed¹, Letisia Cortes³, Gaston Kapuku⁴

¹Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, GA, USA
²Institute of Public and Preventive Health, Augusta University, Augusta, GA, USA
³Medical College of Georgia, Augusta University, Augusta, GA, USA
⁴Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA

Abstract

Background: Among breast cancer survivors age > 50 years, deaths due to cardiovascular disease account for 35% of non-cancer related deaths. The increases in cardiovascular disease among breast cancer survivors is due to the cardiotoxic effects of breast cancer treatment and to overlapping risk factors for breast cancer and cardiovascular disease.

Methods: We conducted a study of a sample of 164 breast cancer patients in order to examine the frequency of cardiovascular disease. The overall objective was to examine the frequency of high blood pressure, myocardial infarction, cardiomyopathy, congestive heart failure, stroke, and venous thrombosis/thromboembolism among women who have been diagnosed with stage I-IV breast cancer and who had completed primary therapy for the disease. Data were collected by postal survey and abstraction of electronic medical records.

Results: A high percentage of the women (62.8%) had a reported history of high blood pressure. Fifty percent of the women had a reported history of high cholesterol. About 8.3% of the women were current smokers and 36.0% were former smokers. About 23.8% of the women had a reported history of diabetes. About 4.9% of the women had a reported history of congestive heart failure and 6.1% had a history of stroke.

Discussion: Additional studies are needed of cardiovascular risk factors and adverse cardiovascular events among breast cancer survivors. Of particular concern is whether patients with hypertension, hypercholesterolemia, and diabetes are receiving appropriate therapy to reduce their cardiovascular risk and prevent morbidity and mortality from adverse cardiovascular events.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/4.0/

*Correspondence to: Dr. Steven Coughlin, Professor, Department of Population Health Sciences, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912, USA; scoughlin@augusta.edu.

Conflicts of Interest
None.

Ethical Approval
This study was approved by the Augusta University Institutional Review Board.

Informed Consent
The informed consent of research participants was obtained.
Keywords
Breast cancer survivors; cardiomyopathy; cardiovascular disease; congestive heart failure; hypertension; stroke; venous thrombosis

Introduction
Cardiovascular disease is the leading cause of death in women in general and among breast cancer survivors in particular [1, 2]. Among breast cancer survivors aged fifty and more, deaths due to cardiovascular disease account for 35% of non-cancer related deaths [1]. Cardiovascular disease is the leading cause of death in patients with breast cancer over fifty years of age [3]. The increases in cardiovascular disease among breast cancer survivors is due to the cardiotoxic effects of breast cancer treatment (e.g. anthracycline chemotherapy and biologic therapy) and to overlapping risk factors for breast cancer and cardiovascular disease (e.g. age, physical inactivity, obesity, insulin resistance, alcohol consumption, hormone replacement therapy) [4]. There is a well-established link between anthracycline chemotherapy and cardiomyopathy and congestive heart failure [1, 2].

As a result, doses of anthracycline such as doxorubicin have decreased. Trastuzumab, a biological therapy that targets the HER-2 receptor can lead to reversible congestive heart failure [5-7]. Tamoxifen used as an adjuvant therapy for breast cancer increases risk of venous thrombosis [2]. We conducted a study of a sample of breast cancer patients in order to examine the frequency of cardiovascular disease. The overall objective was to examine the frequency of congestive heart failure, high blood pressure, myocardial infarction, cardiomyopathy, stroke, and venous thrombosis/thromboembolism among women who have been diagnosed with stage I-IV breast cancer and had completed primary therapy for the disease. The specific aim was to examine the relationship between congestive heart failure and cancer treatment with chemotherapy.

Methods
Data are from the Cardiovascular Disease outcomes among Breast Cancer Survivors study (CVDBCS), a cross-sectional study among breast cancer survivors. Non-institutionalized women were eligible to take part in the study if they had been diagnosed with breast cancer and completed primary therapy at Augusta University Health or the Georgia Cancer Center; and resided in Augusta-Richmond County or Columbia County, GA, or in Aiken County, SC. Data were collected using postal survey questionnaires and abstraction of electronic medical records.

The mailings were sent to 1,000 potential research participants. A sequential mailing protocol was followed using a modified Dillman method. An advance letter was mailed to the women by the study principal investigator (SSC). The letter provided information about the study (purpose, potential benefits, and risks). Three weeks later, a survey consent letter was mailed to those who had not opted out along with a copy of the survey questionnaire and a pre-addressed, stamped return envelope. Women who had not opted out or returned a completed questionnaire were sent a reminder postcard four weeks later.
Outcome Measures

Information about cardiovascular risk factors and diseases (congestive heart failure, high blood pressure, diabetes, myocardial infarction, cardiomyopathy, stroke, venous thrombosis or thromboembolism), breast cancer (stage-at-diagnosis, date of diagnosis), and breast cancer treatment) was collected via postal survey and abstracted from electronic medical records. Survey responses were checked for completeness and then coded and entered into an electronic database.

Descriptive analyses and logistic regression methods were used to examine predictors of congestive heart failure, using a forward-selection model building strategy. We present adjusted odds ratios (OR) and 95% confidence Intervals (95% CI). Significance level was set at $\alpha = 0.05$. Levels of statistical significance were determined using Wald chi-square tests and Log-likelihood ratio tests. The goodness-of-fit of the model model was examined using the Log-likelihood ratio test.

Result

A total of 164 women completed the study questions (response rate 16.4%). The mean age of the women was 67 years (Table 1). Among all participants, 66.7% were white, 29.5% were African-American, and the remainder were of other races. More than half (58.4%) of the women were insured through Medicare and 29.2% held private insurance. With respect to breast cancer stage at diagnosis, 19.8% of the women had ductal carcinoma in situ, 26.8% had stage I disease, 21.0% had stage II disease, 8.9% had stage III disease, and 5.1% had stage IV disease. The mean number of years since diagnosis was 9.4 years. About 54.9% of the women reported receiving chemotherapy and only 4.9% reported biologic/targeted therapy.

A high percentage of the study participants (62.8%) reported a history of high blood pressure; 50% had high cholesterol; and 8.3% were current cigarette smokers (Table 2). About 23.8% of the women had a reported history of diabetes. About 4.9% of the women had a reported history of congestive heart failure and 6.1% had a history of stroke. Similar results were obtained based upon information recorded in the medical records (Table 3). In a logistic regression analysis of predictors of congestive heart failure, time since diagnosis (years) was a significant predictor of congestive heart failure (odds ratio [OR] = 1.14, 95% confidence interval [CI] 1.03-1.23). Women who had received chemotherapy were more likely to have a history of congestive heart failure (OR = 1.43, 95% CI 0.57-361.67); the association was of borderline significance (p=.1059).

Discussion

In this study of breast cancer survivors treated at a large academic medical center in the southern United States, a high percentage of patients had one or more cardiovascular risk factors. Almost two-thirds of the women had a history of high blood pressure and half had a history of high cholesterol. About one in five had a history of diabetes. Forty-four percent were current or former cigarette smokers. The prevalence of cardiovascular risk factors in this population is of concern both because it may increase risk of adverse cardiovascular
events such as congestive heart failure and stroke, and because breast cancer survivors have an increased risk of adverse cardiovascular events due to primary treatment for the disease. Aside from hypertension, the most common adverse cardiovascular disease outcomes were stroke (5.1%), venous thrombosis (5.1%), congestive heart failure (4.4%), and cardiomyopathy (4.4%). Only 1.3% of the women had a recorded history of heart attack. Breast cancer survivors who receive tamoxifen therapy have an increased risk of deep vein thrombosis and pulmonary embolism [8].

Women who had received chemotherapy were more likely to have a history of congestive heart failure. This is consistent with the well-established link between anthracycline chemotherapy and congestive heart failure [1, 2]. However, we lacked information about the specific chemotherapy regimens received by the patients. Cardiovascular disease is the leading cause of death for women with ductal carcinoma in situ or stage I disease, and for women aged > 80 years with stage II disease [9]. A recent systematic review found that women with a history of breast cancer have a higher risk of breast cancer mortality than their cancer-free counterparts [10]. However, in the National Institute of Environmental Health Sciences Sister Study Cohort, changes over time in cardiovascular disease risk, adiposity measures, and blood pressure were similar between women who developed an incident breast cancer and those who did not [9].

Over half of the patients in the current study were over 60 years of age. Older breast cancer survivors cope with health issues related to cancer treatment and the aging process, including comorbidities, symptoms, physical functioning, nutrition, and physical activity [11]. Additional research is needed to examine therapeutic interventions to address the health conditions older breast cancer survivors are coping with [11]. Cardiotoxicity is a major concern during breast cancer therapy and may impede the normal chemotherapy regimen [1]. Cardiovascular side effects of chemotherapy used in cancer therapy is increasingly becoming a medical problem of paramount importance since the number of cancer survivors is increasing. Common chemotherapy agents such as adriamycin and trastuzumab may induce cardiac malfunction that is reversible after stopping the treatment and/or using ACE inhibitors and/or beta blockers [1, 2]. Cardiac malfunction is highly prevalent in young breast cancer survivors treated with anthracycline [3].

It is important to develop early markers of cardiotoxicity to prevent irreversible damage. This can be accomplished by detecting early heart function derangement than relying on ejection fraction which is less sensitive to capture subtle heart malfunction. Monitoring diastolic function has been proved to be more sensitive to effect of these medications in the increasing numbers cancer survivors. Such effort will encompass using Doppler and strain rate imaging, cardiac MRI, and biomarkers (e.g. troponin, BNP) in a large population to identify precursors of cardiac malfunction in breast cancer treated patients and determine who should be treated at an early stage.

With respect to limitations, misclassification bias is a possibility due to the use of self-reported information. However, recorded information about cardiovascular risk factors and adverse cardiovascular outcomes was also obtained from electronic medical records. The results of this study may not be generalizable to other populations of breast cancer survivors.
However, the sample was diverse by race, socioeconomic factors, and history of breast cancer diagnosis and treatment. Additional studies are needed of cardiovascular risk factors and adverse cardiovascular events among breast cancer survivors. Of particular concern is whether patients with hypertension, hypercholesterolemia, and diabetes are receiving appropriate therapy to reduce their cardiovascular risk and prevent morbidity and mortality from adverse cardiovascular events.

References

1. Gulati M, Mulvagh SL (2018) The connection between the breast and heart in women: breast cancer and cardiovascular disease. Clin Cardiol 41: 253–257. [PubMed: 29446841]

2. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V et al. (2018) Cardiovascular disease and breast cancer: where these two entities intersect. A scientific statement from the American Heart Association. Circulation 137: e30–e66. [PubMed: 29437116]

3. Cardinale D, Caruso V, Cipolla CM (2018) The breast cancer patient in the cardioncology unit. J Thoracic Dis 10: S4306–S4322.

4. Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK et al. (2013) Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv 7: 253–261. [PubMed: 23417882]

5. Yu AF, Singh JC, Wang R, Liu JE, Eaton A et al. (2017) Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist 22: 642–647. [PubMed: 28341761]

6. Nowsheen S, Viscuse PV, O’Sullivan CC, Sandhu NP, Haddad TC et al. (2017) Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer. Curr Breast Cancer Rep 9: 173–182. [PubMed: 29225726]

7. Seferina SC, De Boer M, Derksen MW, Van Den Berkmortel F, Van Kampen RJ et al. (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice. Oncologist 21: 554–562.

8. Hernandez RK, Sorensen HT, Pedersen L et al. (2009) Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 115: 4442–4449. [PubMed: 19569248]

9. Anderson C, Nichols HB, Deal AM, Park Yong Moon Mark, Sandler Dale P et al. (2018) Changes in cardiovascular disease risk and risk factors among women with and without breast cancer. Cancer 124: 4512–4519. [PubMed: 30291812]

10. Gernaat SAM, Ho PJ, Rijnberg N, Emaus MJ, Baaket LM et al. (2017) Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat 164: 537–555. [PubMed: 28503723]

11. Coughlin SS, Paxton RJ, Moore N et al. (2019) Survivorship issues in older breast cancer survivors. Breast Cancer Res Treat 174: 47–53. [PubMed: 30506112]
Table 1:

Characteristics of study participants, Cardiovascular Disease Outcomes among Breast Cancer Survivors Study (n=164).

| Characteristic                  | Frequency (%) |
|--------------------------------|---------------|
| Age (years) mean (SD) (N=163)   | 67 (41.1)     |
| Race (N=156)                   |               |
|       White, Non-Hispanic       | 104 (66.7)    |
|       African American, Non-Hispanic | 46 (29.5)  |
|       Other¹                    | 6 (3.9)       |
| Annual Income (N=46)           |               |
|       <$20,000                  | 17 (10.4)     |
|       $20,000-$34,999          | 17 (10.4)     |
|       $35,000-$49,999          | 17 (10.4)     |
|       $50,000-$64,999          | 14 (8.5)      |
|       $65,000-$79,999          | 8 (4.9)       |
|       $80,000 +                | 38 (23.2)     |
|       Missing²                 | 53 (32.3)     |
| Number of people in household (N=160) |               |
|       1                        | 48 (30.0)     |
|       2                        | 83 (51.9)     |
|       3 +                      | 29 (18.1)     |
| Employment status (N=163)      |               |
|       Retired                  | 99 (60.7)     |
|       Employed                 | 34 (20.9)     |
|       On disability            | 16 (9.8)      |
|       Homemaker                | 9 (5.5)       |
|       Temporarily unemployed   | 4 (2.5)       |
| Marital status (N=163)         |               |
|       Married/Partner          | 84 (51.5)     |
|       Single                   | 24 (14.7)     |
|       Widowed                  | 32 (19.6)     |
|       Separated/Divorced       | 23 (14.1)     |
| Characteristic                     | Frequency (%) |
|-----------------------------------|---------------|
| **Education** (N=157)             |               |
| Less than HS                      | 5 (3.2)       |
| HS or equivalent                  | 42 (26.8)     |
| Some college                      | 27 (17.2)     |
| Associate degree                  | 22 (14.0)     |
| Bachelor degree                   | 27 (17.2)     |
| Graduate degree                   | 34 (21.7)     |
| **Health Insurance** (N=161)      |               |
| Medicare                          | 94 (58.4)     |
| Private insurance                 | 47 (29.2)     |
| Other^3                           | 20 (12.4)     |
| **Perceived general health** (N=162) |          |
| Excellent                         | 16 (9.9)      |
| Very good                         | 58 (35.8)     |
| Good                              | 59 (36.4)     |
| Fair                              | 24 (14.8)     |
| Poor                              | 5 (3.1)       |
| **Breast cancer stage at diagnosis** (N=157) |        |
| Ductal carcinoma in situ          | 31 (19.8)     |
| Stage I                           | 42 (26.8)     |
| Stage II                          | 33 (21.0)     |
| Stage III                         | 14 (8.9)      |
| Stage IV                          | 8 (5.1)       |
| Don't know                        | 29 (18.5)     |
| **Time since diagnosis** (in years) mean (SD) (N=155) | 9.4 (8.8) |
| **Type of treatment received** (N=164) |           |
| None                              | 2 (1.2)       |
| Surgery                           | 161 (98.2)    |
| Radiation                         | 111 (67.7)    |
| Chemotherapy                      | 90 (54.9)     |
| Hormone therapy                   | 74 (45.1)     |
| Characteristic                  | Frequency (%) |
|--------------------------------|---------------|
| Biologic/Targeted therapy      | 8 (4.9)       |
Table 2:
Self-reported History of Cardiovascular Disease/Risk Factors and among Breast Cancer Survivors (n=164).

| Cardiovascular disease/risk factor     | Frequency (%) |
|---------------------------------------|---------------|
| Heart attack                          | 3 (1.8)       |
| Congestive heart failure              | 8 (4.9)       |
| Stroke                                | 10 (6.1)      |
| Diabetes                              | 39 (23.8)     |
| High blood pressure                   | 103 (62.8)    |
| High cholesterol                      | 82 (50.0)     |
| Cigarette smoking status              | 13 (8.3)      |
| Current smoker                        |               |
| Former smoker                         | 56 (36.0)     |
| Never smoker                          | 87 (55.7)     |
Table 3:
Recorded History of Cardiovascular Risk Factors and Cardiometabolic Disease among Breast Cancer Survivors, from Abstraction of Electronic Medical Records (n=164).

| Factor                  | Frequency (%) |
|-------------------------|---------------|
| High Blood Pressure     | 102 (64.6)    |
| High Cholesterol        | 75 (47.5)     |
| Congestive Heart Failure| 7 (4.4)       |
| Heart Attack            | 2 (1.3)       |
| Stroke                  | 8 (5.1)       |
| Cardiomyopathy          | 7 (4.4)       |
| Venous Thrombosis       | 8 (5.1)       |